Brought to you by 
Gritstone and bluebird bio enter cell therapy partnership
22 Apr 2022
Executive Summary
Gritstone Oncology agreed to use its EDGE personalized neoantigen platform to provide ten tumor-specific targets (and T-cell receptors (TCRs) directed to those targets) for cell therapy and gene editing firm bluebird bio Inc.
Deal Industry
- Pharmaceuticals
-
Digital Health
- Artificial Intelligence
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
-
Drug Discovery Tools
- Bioinformatics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Gritstone and bluebird bio enter cell therapy partnership
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice